Neuraxis signs exclusive option agreement with university of michigan for innovative gastrointestinal device

Carmel, ind., nov. 08, 2023 (globe newswire) -- neuraxis, inc. (“neuraxis,” or the “company”) (nyse american: nrxs), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced it has executed an exclusive option agreement with the university of michigan for the exclusive licensing of its innovative rectal expulsion device (red). the red redesigns the balloon expulsion testing workflow to directly simplify anorectal function testing downstream to any gastroenterologist's office.   during the option agreement period, neuraxis intends to evaluate the vast market potential for red.
NRXS Ratings Summary
NRXS Quant Ranking